About Forbion
Forbion is a venture capital firm founded in 2000. It is primarily based out of Naarden, Netherlands. As of Jun 2026, Forbion is an active investor, having invested in 135 companies, with 16 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series A round of RQ Bio Overall, Forbion portfolio has seen 17 IPOs and 35 acquisitions including key companies like argenx, Abiomed and Bluebird Bio. A lot of funds co-invest with Forbion, with names like RA Capital Management sharing a substantial percentage of its portfolio. Forbion has team of 48 people including 16 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 6 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Forbion's List of Top Investments
Forbion has a portfolio of 135 companies. Their most notable investments are in Azafaros and Sparrow Pharmaceuticals.Their portfolio spans across United States, United Kingdom, Netherlands and 13 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 7 other sectors, across stages such as Series A, Series B and 6 more. Here is the list of top investments by Forbion:1. argenx
Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llama's and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.
Key facts about argenx
- Founded Year: 2008
- Location: Ghent (Belgium)
- Annual Revenue: €1B+ as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $61.9M
- Employee Count: 2,227 as on May 31, 2026
- Investors: HBM Healthcare Investments, Avoro Capital and 20 Others
- Latest Funding Round: Post IPO, Mar 24, 2022, $*****
- Highlight: Public
2. Abiomed
Developer of heart pumps for blood circulation and oxygenation. It offers Impella heart pump, is an Intra-Aortic Balloon Catheter that provides hemodynamic support to the heart. It also, offers OXY-1 System compact cardiopulmonary support system, with an integrated oxygen concentrator that provides an independent oxygen source to support mobility.
Key facts about Abiomed
- Founded Year: 1981
- Location: Danvers (United States)
- Annual Revenue: $1B+ as on Mar 31, 2022
- Stage: Acquired
- Employee Count: 2,131 as on Jul 09, 2025
- Investors: EW Healthcare Partners, Forbion and 1 Other
- Latest Funding Round: Grant (prize money), Aug 25, 2010, $*****
- Highlight: Acquired
3. Bluebird Bio
Developer of gene therapies for severe genetic and rare diseases. The company's products include Lenti-D for Childhood Cerebral Adrenoleukodystrophy (ALD) and LentiGlobin for rare hemoglobinopathies. The company's other products for multiple myeloma and HPV-associated cancer are in the preclinical stage. The company is also using homing endonuclease and megaTAL gene-editing technologies in a variety of potential applications and disease areas, including hematology and oncology.
Key facts about Bluebird Bio
- Founded Year: 1992
- Location: Cambridge (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $136M
- Employee Count: 317 as on May 31, 2026
- Investors: Thecarlylegroup.fr, Sanofi Ventures and 10 Others
- Latest Funding Round: Post IPO, Jun 03, 2022, $*****
- Highlight: Acquired
Developer of immunotherapies for the treatment of infectious diseases and cancer. The company uses a proprietary arenavirus platform to develop a product pipeline that inlcudes HB-201 and HB-202 for the treatment of Human Papillomavirus-16 positive (HPV16+) cancers.
Key facts about HOOKIPA Pharma
Developer of gene editing technologies for improved tropical crop production. The company focuses on improving crops to be tastier and hardier. It aims to make crops less reliant on pesticides and more resilient to climate change. The company’s technology supports farmers, equipping them against climate change. It helps them to increase their yields.
Key facts about Tropic Biosciences
Forbion's Year-on-Year Investment Trends
Forbion has invested in 135 companies over the last 25 years, with an average of 8 new investments annually in the last 10 years. In 2025, it made 21 investments, while as of Jun 2026, it has made 10 investments in this year. Its most recent first time investment was in RQ Bio and most recent follow-on round was in Mestag Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 8 | 2 | 10 |
2025 | 15 | 6 | 21 |
2024 | 14 | 7 | 21 |
2023 | 10 | 2 | 12 |
2022 | 5 | 2 | 7 |
2021 | 10 | 3 | 13 |
2020 | 5 | 4 | 9 |
2019 | 2 | 2 | 4 |
2018 | 6 | 1 | 7 |
2017 | 4 | 3 | 7 |
Forbion's Investments by Stage
Forbion has made 49 investments in Series A stage with an average round size of $74.8M, 35 investments in Series B stage with an average round size of $67.6M and 14 investments in Series C stage with an average round size of $53.1M.Stage of entry | No. of Investments |
|---|---|
Series A | 49 |
Series B | 35 |
Series C | 14 |
Seed | 6 |
Post IPO | 3 |
Others | 5 |
Note: We have considered here, only first round of investments
Forbion's Investments by Sector
Forbion has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Enterprise Applications and Food and Agriculture Tech. Notably, it has invested in 119 Tech companies, 104 Enterprise (B2B) companies, 22 Software companies and at least 11 companies focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 102 |
High Tech | 12 |
Sustainability Tech | 12 |
Enterprise Applications | 8 |
Food and Agriculture Tech | 3 |
Others | 9 |
Note: We have considered here, only first round of investments
Forbion's Investments by Geography
Forbion has made most investments in United States (37), followed by United Kingdom where it has made 26 investments.Country | No. of Investments |
|---|---|
United States | 37 |
United Kingdom | 26 |
Netherlands | 9 |
Germany | 7 |
Switzerland | 7 |
Others | 26 |
Note: We have considered here, only first round of investments
Forbion's recent investments
Forbion has made 10 investments in 2026 so far. RQ Bio and Memento Medicines are the latest among them.Here are the most recent investments by Forbion:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 24, 2026 | United Kingdom | Series A | 2783 | [+4] | |
Jun 03, 2026 | - | Series A | 1792 | ||
May 20, 2026 | United States | Series A | 5387 | ||
Apr 28, 2026 | Belgium | Series A | 3746 | ||
Mar 17, 2026 | United Kingdom | Series A | 3073 | [+3] |
IPOs and Publicly Listed companies in Forbion's Portfolio
17 of Forbion's portfolio companies have become public. MapLight got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2025 at marketcap of $704M and enGene got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Forbion's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 27, 2025 | Jul 18, 2025 | Series D | 1587 | |
Nov 01, 2023 | Jan 26, 2015 | Series B | 3646 | |
Mar 31, 2021 | Jul 07, 2019 | Series B | 8173 | |
Feb 08, 2021 | Jan 14, 2021 | Series A | 7582 | |
Feb 05, 2021 | Jun 25, 2025 | Post IPO | 3550 |
Acquired companies in Forbion's Portfolio
35 companies from Forbion's portfolio have been acquired. The most recent acquisition was Capstan Therapeutics in Jul 2025 by AbbVie for $*****.Here are Forbion's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 01, 2025 | Mar 05, 2024 | Series B | 7177 | |
Feb 21, 2025 | Mar 12, 2010 | Series B | 8770 | |
Jan 02, 2025 | Mar 01, 2021 | Series B | 9387 | |
May 15, 2024 | - | - | 1421 | |
May 02, 2024 | Sep 07, 2023 | Series B | 2375 |
Team profile of Forbion
Forbion has a team of 48 members including 16 Partners, 6 Venture Partners and 9 Principals located in Netherlands, United Kingdom and 4 more locations. Forbion's team sits on the board of 2 companies.Here is a list of top team members in Forbion:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Amsterdam | - | ||
Partner | Almere | - | ||
Partner | Naarden | |||
Partner | Amsterdam | - | ||
Partner | Heemstede | |||
Partner | Amsterdam | - | ||
Partner | Cologne | - | ||
Partner | Amsterdam | - | ||
Partner | Amsterdam | - | ||
Partner | Amsterdam | - | - | |
Partner | Amsterdam | - |
Co-investors of Forbion
Over the past 25 years, 607 investors have co-invested in Forbion's portfolio companies. This includes funds and angels.
- Invested before Forbion: Novo Holdings, Novartis Venture Fund and 225 others have invested in rounds before Forbion. There are 6 companies where Novo Holdings has invested before Forbion and 6 companies where Novartis Venture Fund has invested before Forbion.
- Top Co-investors of Forbion: 220 investors entered a company along with Forbion. These include investors like RA Capital Management (12 companies).
- Invested after Forbion: A total of 160 investors have invested in Forbion's portfolio after their investments. Top Investors include Europa (4 companies), Venrock (4 companies) and Orbimed (3 companies).
Recent News related to Forbion
•
AES Corporation Stockholders Approve Acquisition by Global Infrastructure Partners and EQT-Led ConsortiumPR Newswire•Jun 27, 2026•Global Infrastructure Partners, AES, EQT, Frazier Life Sciences and 4 others
•
EQT Life Sciences Participates in RQ Bio's USD 115 Million Series A FinancingPR Newswire•Jun 24, 2026•Frazier Life Sciences, EQT, RQ Bio, Forbion and 6 others
•
•
cAMPfield harvests $180M series A to advance oral IBD drug licensed from NewsoaraFierce Biotech•Jun 18, 2026•Campfield Care, Novo Holdings, Venrock, Abingworth and 2 others
•
EXL Acquires iMerit to Strengthen AI Training and Enterprise‑Scale Platformsintelligence360•Jun 17, 2026•RA Capital Management, Xuanzhu Biology, Adage Capital Management, Forbion and 3 others
•
•
Coultreon Biopharma Secures $125M Series A to Advance Immunology PipelineBioSpace•Apr 28, 2026•Novo Holdings, Forbion, Sofinnova Investments, Finchley Healthcare Ventures and 16 others
•
Mestag Therapeutics Raises $40M in FinancingFinSMEs•Mar 17, 2026•Northpond Ventures, Mestag Therapeutics, Johnson & Johnson, Google Ventures and 3 others
•
Munich’s UVC adds growth stage with €77M, follows Proxima Fusion’s €2B raiseTech Funding News•Mar 13, 2026•Just Climate, Sucden, Five Seasons Ventures, Genoa Ventures and 6 others
•
